Just – Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz

Evotec SE, through its biologics segment Just – Evotec Biologics, has announced an expanded strategic partnership with Sandoz for the development and commercial manufacturing of biosimilars. This expansion aims to add more biosimilars to Sandoz's development pipeline and secure long-term commercial supply guarantees.

The partnership highlights the new J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. This facility will play a crucial role in ensuring a stable supply of biosimilars for Sandoz. Since May 2023, the two companies have worked together to leverage Just – Evotec Biologics’ technology platform, J.DESIGN, for efficient development and manufacturing.

Dr. Matthias Evers, Chief Business Officer of Evotec, stated that the expansion enhances access for patients and validates their strategy to establish a new J.POD® in Toulouse. This collaboration aligns with Evotec's mission to improve global access to medicines.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Evotec AG news